Laetrile and Related Substances | CMS Coverage Update

Summary: The Centers for Medicare & Medicaid Services modified its coverage policy on Laetrile and related substances, effective May 15, 2026. Here's what billing teams need to know before claims hit the queue.

CMS Laetrile coverage policy has been a non-coverage determination for decades — but policy modifications, even to long-standing exclusions, can create claim denial exposure if your charge capture and documentation processes aren't aligned with the updated language. This policy does not list specific CPT or HCPCS codes in the available data, which we'll address directly below. If your organization bills for alternative, complementary, or investigational cancer treatments under Medicare, this update warrants a close look before the May 15, 2026 effective date.

Quick-Reference Table

CMS Laetrile Coverage Criteria and Medical Necessity Requirements 2026

Laetrile — also known as amygdalin or Vitamin B17 — has been the subject of a long-standing CMS non-coverage position. The Centers for Medicare & Medicaid Services does not consider Laetrile or related substances medically necessary for the treatment of cancer or any other condition under Medicare. This is not new. What matters now is that the policy has been formally modified as of May 15, 2026, and you need to verify whether the updated language changes any of the specific criteria, definitions, or scope.

The core medical necessity question here has always been the same: CMS does not recognize Laetrile as safe or effective under FDA or NCI standards. Medicare will not reimburse for the drug itself, its administration, or related services when Laetrile is the primary agent being delivered. The modification to this coverage policy may refine how CMS defines "related substances" — which is the phrase that creates the most ambiguity for billing teams.

The phrase "related substances" is where the real billing exposure lives. If your infusion center or oncology practice administers compounds alongside or instead of FDA-approved therapies, and any of those compounds fall under CMS's expanded definition of "related substances," you may be billing for non-covered services without realizing it. Check the updated policy text directly at the CMS source before May 15, 2026.

Prior authorization is not typically a factor in non-coverage determinations — CMS won't authorize something it categorically excludes. But that doesn't mean prior auth is irrelevant to your workflow. If a patient pushes back on a denial and your MAC gets involved, having documentation that you reviewed the coverage policy before administering treatment protects your practice.

CMS Laetrile Exclusions and Non-Covered Indications

CMS has maintained that Laetrile and amygdalin are not covered under Medicare on the grounds that they are not FDA-approved and lack demonstrated clinical efficacy. The non-coverage position extends to the substance itself, its derivatives, and — critically — services rendered primarily in connection with its administration.

The real issue here is the "related substances" language. Billing teams sometimes assume that because they aren't billing for Laetrile directly, they're in the clear. They're not. If a claim includes administration fees, IV setup, or infusion services connected to a non-covered substance, those services inherit the non-coverage status. CMS has been consistent on this — the substance drives the claim's fate, not just the administration code.

Watch for any policy language that expands or narrows what counts as a "related substance." The 2026 modification could tighten or broaden that definition. Until you've read the updated text, treat any amygdalin-adjacent compound with the same caution you'd apply to Laetrile itself.

Coverage Indications at a Glance

This policy does not list specific CPT, HCPCS, or ICD-10 codes in the available data. Do not assume any code is covered or excluded without consulting the full updated policy text.

CMS Laetrile Billing Guidelines and Action Items 2026

This is a non-coverage policy. Your action items are defensive — the goal is to make sure no claim slips through that creates a Medicare fraud or billing compliance issue.

CPT, HCPCS, and ICD-10 Codes for Laetrile Under CMS Policy

This policy does not list specific CPT, HCPCS, or ICD-10 codes in the available data. Do not fabricate codes, and do not assume a code is covered or excluded without verifying against the full published policy.

That said, here is the practical guidance for Laetrile billing:

What to Watch For

If your practice administers any compound that could be classified as Laetrile or an amygdalin derivative, the following code categories are commonly associated with drug administration and infusion services that could be bundled into a denied claim:

• Drug administration codes (CPT 96360–96379 range): Infusion and injection codes. These codes become non-covered when the substance being administered is itself non-covered under CMS policy.
• Drug supply codes (HCPCS J-codes): There is no assigned J-code for Laetrile because it is not FDA-approved. Any attempt to bill a J-code for amygdalin or a derivative will fail.
• ICD-10 diagnosis codes for neoplasm (C00–C96 range): Commonly used to justify cancer-related treatments. A cancer diagnosis does not make a non-covered treatment covered. CMS does not cover Laetrile regardless of the underlying diagnosis.

The absence of a specific code in CMS's policy data is not a green light. It means the policy applies categorically, without exception, to the substance and related services — regardless of how you code the claim.

If you are uncertain how to code a service that may touch this coverage area, talk to your compliance officer or a certified professional coder with Medicare billing experience before the May 15, 2026 effective date.